ONCOVISTA INNOVATIVE THERAPIES, INC: 10-Q filed 2015-11-12

Name: ONCOVISTA INNOVATIVE THERAPIES, INC: 10-Q filed 2015-11-12
Creator: ONCOVISTA INNOVATIVE THERAPIES, INC

What ONCOVISTA INNOVATIVE THERAPIES, INC reported in its quarterly report filed 2015-11-12 (fiscal Q3 2015): 23 published measures, 62 facts as tagged in accession 0001144204-15-064255.

This filing

Form: 10-Q (quarterly report)
Filed: 2015-11-12
Fiscal period: fiscal Q3 2015
Accession: 0001144204-15-064255 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ONCOVISTA INNOVATIVE THERAPIES, INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2015-09-30	61,270	USD
At 2014-12-31	12,514	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2015-09-30	6,651,034	USD
At 2014-12-31	5,675,674	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2015-09-30	-6,589,764	USD
At 2014-12-31	-5,663,160	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2015-09-30	61,270	USD
At 2014-12-31	12,514	USD
At 2014-09-30	75,631	USD
At 2013-12-31	44,898	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-326,098	USD	92
2015-01-01 to 2015-09-30	-1,699,421	USD	273
2014-07-01 to 2014-09-30	226,846	USD	92
2014-01-01 to 2014-09-30	-973,437	USD	273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Unit	Days
2015-07-01 to 2015-09-30	USD	92
2015-01-01 to 2015-09-30	USD	273
2014-07-01 to 2014-09-30	USD	92
2014-01-01 to 2014-09-30	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2015-09-30	-27,601,934	USD
At 2014-12-31	-25,902,513	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2015-09-30	0	USD
At 2014-12-31	0	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	0	USD	273
2014-01-01 to 2014-09-30	995	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-317,397	USD	92
2015-01-01 to 2015-09-30	-1,678,453	USD	273
2014-07-01 to 2014-09-30	-286,754	USD	92
2014-01-01 to 2014-09-30	-819,841	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2015-09-30	61,270	USD
At 2014-12-31	12,514	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2015-09-30	5,951,034	USD
At 2014-12-31	4,975,674	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2015-09-30	1,964,965	USD
At 2014-12-31	1,671,909	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	317,397	USD	92
2015-01-01 to 2015-09-30	1,678,453	USD	273
2014-07-01 to 2014-09-30	286,754	USD	92
2014-01-01 to 2014-09-30	819,841	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	161,187	USD	92
2015-01-01 to 2015-09-30	483,165	USD	273
2014-07-01 to 2014-09-30	125,122	USD	92
2014-01-01 to 2014-09-30	400,426	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2015-09-30	23,558,530	shares
At 2014-12-31	23,558,530	shares

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2015-09-30	39,458	USD
At 2014-12-31	39,458	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2015-09-30	39,458	USD
At 2014-12-31	39,458	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2015-09-30	2,990,771	USD
At 2014-12-31	2,579,436	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	156,210	USD	92
2015-01-01 to 2015-09-30	1,195,288	USD	273
2014-07-01 to 2014-09-30	161,632	USD	92
2014-01-01 to 2014-09-30	419,415	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	0	USD	273
2014-01-01 to 2014-09-30	477	USD	273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-8,701	USD	92
2015-01-01 to 2015-09-30	-20,968	USD	273
2014-07-01 to 2014-09-30	513,600	USD	92
2014-01-01 to 2014-09-30	-153,596	USD	273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	293,056	USD	273
2014-01-01 to 2014-09-30	147,681	USD	273

Inspect the source

Entity: ONCOVISTA INNOVATIVE THERAPIES, INC / CIK 0001094847
Captured: 2026-09-23 02:46 UTC
SEC response SHA-256: 034ecc655296ec55707e21b2011e7bc05aab2b1bd1d5e47c9d631e0e4310eac5

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001094847.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))